Cabaletta Bio, Inc.

Informe acción NasdaqGS:CABA

Capitalización de mercado: US$91.4m

Cabaletta Bio Dirección

Dirección controles de criterios 2/4

El CEO de Cabaletta Bio es Steven Nichtberger , nombrado en Jan 2017, tiene una permanencia de 7.83 años. compensación anual total es $4.81M, compuesta por 12.4% salario y 87.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.76% de las acciones de la empresa, por valor de $2.52M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.8 años, respectivamente.

Información clave

Steven Nichtberger

Chief Executive Officer (CEO)

US$4.8m

Compensación total

Porcentaje del salario del CEO12.4%
Permanencia del CEO7.8yrs
Participación del CEO2.8%
Permanencia media de la dirección3yrs
Promedio de permanencia en la Junta Directiva4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

May 22
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Dec 28
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steven Nichtberger en comparación con los beneficios de Cabaletta Bio?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$1mUS$213k

-US$12m

Compensación vs. Mercado: La compensación total de Steven($USD4.81M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).

Compensación vs. Ingresos: La compensación de Steven ha aumentado mientras la empresa no es rentable.


CEO

Steven Nichtberger (63 yo)

7.8yrs

Permanencia

US$4,808,279

Compensación

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
David Chang
Chief Medical Officer5.4yrsUS$2.10m0%
$ 0
Gwendolyn Binder
President of Science & Technologyno dataUS$2.34m0.041%
$ 37.4k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Anup Marda
Chief Financial Officer5.8yrsUS$1.53msin datos
Qing Yuan
Chief Technology Officerless than a yearsin datossin datos
Samik Basu
Chief Scientific Officer3yrssin datossin datos
Michael Gerard
General Counsel & Secretary3.2yrssin datossin datos
Heather Harte-Hall
Chief Compliance Officer3yrssin datossin datos
Nicolette Sherman
Chief Human Resources Officerno datasin datossin datos
Arun Das
Chief Business Officer2.8yrssin datossin datos

3.0yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CABA se considera experimentado (3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Richard Henriques
Independent Director5.8yrsUS$259.20k0%
$ 0
Carl June
Member of Scientific Advisory Board4.3yrssin datossin datos
Mark Simon
Independent Director6.1yrsUS$260.15k0.29%
$ 267.7k
Brian Daniels
Member of Scientific Advisory Board3.4yrsUS$202.24ksin datos
Scott Brun
Independent Director3.4yrsUS$255.83k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board4.8yrssin datossin datos
Jay Siegel
Member of Scientific Advisory Boardno datasin datossin datos
Drew Weissman
Member of Scientific Advisory Board2.9yrssin datossin datos
Catherine Bollard
Independent Director5.6yrsUS$255.43k0.0021%
$ 1.9k

4.8yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de CABA se considera experimentada (4.8 años de antigüedad promedio).